KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Gross Margin for 5 consecutive years, with 59.83% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 24126.0% year-over-year to 59.83%, compared with a TTM value of 4.99% through Dec 2025, down 1812.0%, and an annual FY2025 reading of 4.99%, down 1812.0% over the prior year.
  • Gross Margin was 59.83% for Q4 2025 at Recursion Pharmaceuticals, up from 183.81% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q1 2021 and bottomed at 183.81% in Q3 2025.
  • Average Gross Margin over 5 years is 2.04%, with a median of 12.06% recorded in 2023.
  • Peak annual rise in Gross Margin hit 24126bps in 2025, while the deepest fall reached -23750bps in 2025.
  • Year by year, Gross Margin stood at 100.0% in 2021, then tumbled by -79bps to 20.74% in 2022, then crashed by -55bps to 9.28% in 2023, then tumbled by -2055bps to 181.43% in 2024, then skyrocketed by 133bps to 59.83% in 2025.
  • Business Quant data shows Gross Margin for RXRX at 59.83% in Q4 2025, 183.81% in Q3 2025, and 4.88% in Q2 2025.